Eli Lilly has made a significant move into the vaccine sector, acquiring three private vaccine companies for nearly $4 billion. The deals include up to $1.5 billion for Curevo, which is developing a shingles vaccine, $780 million for LimmaTech Biologics targeting staph infections, and $1.55 billion for Vaccine Company, focused on an Epstein-Barr virus vaccine. This marks Lilly’s return to a category it has been absent from for years, signaling a strategic shift under the leadership of former FDA vaccine regulator Dr. Peter Marks.
The implications for the financial markets are noteworthy. While these vaccines are still in early development stages, they target unmet medical needs, potentially positioning Lilly to capture market share in a competitive landscape. Analysts suggest that a more tolerable shingles vaccine could challenge GSK’s Shingrix, which generated $4.8 billion in sales in 2025. Additionally, the Epstein-Barr virus vaccine could address a significant health burden, given the virus’s link to various serious conditions.
Investors should monitor these developments closely, as successful advancement through clinical trials could unlock substantial revenue opportunities for Lilly, particularly if they can differentiate their products in a crowded market.
Source: cnbc.com